Supernus Pharmaceuticals Stock News

Mitsubishi UFJ Asset Management UK Ltd. acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 35,000 shares of the specialty pharmaceutical companys stock, valued at approximately $933,000. Mitsubishi UFJ Asset Management UK Ltd. owned []

Biopharmaceutical company Supernus Pharmaceuticals discloses a ransomware attack, the Hive ransomware claims to have stolen company data.

Foundry Partners LLC decreased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 90.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,597 shares of the specialty pharmaceutical companys stock after selling 168,308 shares during the period. Foundry Partners LLCs holdings in []

Equities analysts predict that Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will announce $143.73 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Supernus Pharmaceuticals earnings. The highest sales estimate is $150.04 million and the lowest is $139.66 million. Supernus Pharmaceuticals reported sales of $143.56 million in the same quarter last []

The attack had no significant impact on the business and did not cause any significant disruption to Company’s operations

The attack had no significant impact on the business and did not cause any significant disruption to Companys operations

Acquisition strengthens Parkinson’s disease portfolio and diversifies revenue and cash flow Acquisition strengthens Parkinson’s disease portfolio and diversifies revenue and cash flow

ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021.

Marshall Wace North America L.P. bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 63,084 shares of the specialty pharmaceutical companys stock, valued at approximately $1,943,000. Several other institutional investors and []

ROCKVILLE, Md., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Companys management will participate in a fireside chat as part of the Piper Sandler 33 rd Annual Virtual Healthcare Conference, being held November 29 December 2, 2021. The Company will also host investor meetings on Wednesday, December 1, 2021.

If you''re a trend trader, consider that the strongest clear trend on the hourly chart exists on the 20 hour timeframe. The post Supernus Pharmaceuticals Inc (SUPN): Price Now Near $34.24; Daily Chart Shows An Uptrend on 100 Day Basis appeared first on ETF Daily News .

Market data depicted in this Oxcarbazepine Drug market report puts light on the macro-economic pointers with its principal market trends. It also shows the competition level in the market among the main organizations and profiles. Some of the chief terms

Related Stocks: DHHC , GFX , VYGG , SUPN , BKCC , DISH , INVA , GSBD , SIERU , GACQU , CENH , GIWWU , CAP , DEH , MAAC ,

Amalgamated Bank acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 25,614 shares of the specialty pharmaceutical companys stock, valued at approximately $789,000. Several other hedge funds have also recently added to or reduced their stakes []

ROCKVILLE, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen